Waqoo (4937) · InitiativeAdvanced
Construction of a cell-culture processing facility
First written in FY2024. 3 of 4 entries say "Advanced", first in FY2025-H1. Latest entry: 2026-09-14.
4entries
3years
1from disclosures
How it moved
Same theme, other companies
Establishment of a new cell culture and processing facility by セルプロジャパンA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- 2026-09-14AdvancedOther Disclosures
「セルプロジャパン株式会社（代表取締役社長 佐俣 文平／神奈川県藤沢市）は、このたび関東信越厚生局より「再生医療等の安全性の確保等に関する法律（再生医療等安全性確保法）」第35条第1項に基づく「特定細胞加工物製造許可」を取得したことをお知らせいたします。」
セルプロジャパンの特定細胞加工物等製造施設について、計画・投資の段階から、法令に基づく製造許可を取得する段階へ進んだ。 - FY2025AdvancedAnnual report
「Total capital expenditure during the consolidated fiscal year was ¥262.284 million, mainly for the Medical Support business.」
Capital expenditure for the Medical Support business, including the cell-culture processing facility, continued; construction in progress increased from ¥75.570 million to ¥319.807 million. Completion was not stated. - FY2025-H1AdvancedAnnual report
「Increase in construction in progress ¥85.698 million」
Construction in progress increased by ¥85.698 million. Completion of the previously disclosed facility plan was not stated, so the facility is not treated as completed. - FY2024First statedAnnual report
「Cell Processing Center ¥224.400 million ¥75.570 million paid Bank borrowings July 2024 March 2025」
The company disclosed a planned ¥224.400 million investment in Cellpro Japan’s cell-culture processing facility, of which ¥75.570 million had been paid, financed through bank borrowings and scheduled for completion in March 2025.